GAITHERSBURG, Md., August 26, 2020 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Company’s Board of Directors has appointed Marvin L. White as Director of Category II to join the Board as of October 1, 2020, the original term of which will expire at the 2023 Annual Shareholders’ Meeting. Mr. White was also appointed a member of the Scientific Review Committee and the Board’s Strategic Operations Committee.
“We welcome Marvin back to the Board of Directors of Emergent,” said Fuad El-Hibri, executive chairman of Emergent BioSolutions. “He provides valuable monetary and control experience gained during his time in the pharmaceutical and health sectors. We look forward to your feedback by advising corporate executives on how to expand and generate shareholder value.”
“I’m very happy to be on the board of administrators of an organization focused on public health,” Mr. White said. “As Emergent executes its expansion strategy, I take the opportunity to work with my outstanding board colleagues and control team to advance the company.
Mr. White has been President and CEO and member of Aptevo Therapeutics Inc. since August 2016. In the past he served on the Board of Emergent from 2010 to 2016. Prior to that, he was CHIEF Financial Officer of St Vincent Health and was guilty of finance, monetary control and patient care for 19 hospitals and 36 joint ventures. Prior to that, he was Chief Financial Officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held senior positions in Corporate Finance and Investment Banking.
About Emergent BioSolutionsEmergent BioSolutions is a global life sciences company whose project is to protect and bring to life. Through our specialized products and our contract production and progression services, we are committed to providing responses that address threats of public fitness. Through social responsibility, our goal is to build safer, forming communities. We aspire to provide peace of mind to our patients and customers so they can focus on what is most vital in their lives. Working together, we plan to protect a billion lives by 2030. For more information, visit www.emergentbioanswers.com. Find us on LinkedIn and stay with us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Safe Harbor Statement This press release includes prospective s within the meaning of the Private Securities Litigation Reform Act of 1995. Any s, other than an old fact, including, but not limited to, s related to the execution of our expansion strategy and the accumulation of value for shareholders, are forward-looking. These leads are based on our existing intentions, ideals, and expectations related to long-term occasions. We can’t make sure that any prospective one is accurate. Investors deserve to be aware that if the underlying assumptions turn out to be erroneous or if unknown threats or uncertainties materialize, the actual effects may differ materially from our expectations. Investors are cautioned not to place undue confidence in any prospective s. The prospects refer only to the date of this press release and, unless required by law, we adopt not to update the leads to reflect new information, occasions or circumstances. A number of vital points can simply make our actual effects differ materially from those indicated through those prospects. Investors deserve to take into account this caution and the threat points known in our periodic reports submitted to the Securities and Exchange Commission during the evaluation of our prospects.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected]
Media Contact: Miko B. Neri Senior Director, Global Communications and Public Affairs 240-631-3392 [email protected]